<!DOCTYPE html>
<html>
<head>
<title>Refpages</title>
<link rel="stylesheet" href="refstyle.css">
</head>

<body>

<!-- refpage 17---------------------------------------------------------------------------------------------------------->
<div class = "title">Vasolidatantia</div>

<div class = "source">
<div class = "quote">
Vasodilatantia: Nitraten, Alfa-blokkers<br>
Lijst van valrisico-verhogende medicaties (p 63)
</div><div class = "ref" name="1">
Nederlandse Vereniging voor Klinische Geriatrie. Preventie van valincidenten bij ouderen. <a href="https://richtlijnendatabase.nl/richtlijn/preventie_van_valincidenten_bij_ouderen/startpagina_-_preventie_van_valincidenten.html">https://richtlijnendatabase.nl/richtlijn/preventie_van_valincidenten_bij_ouderen/startpagina_-_preventie_van_valincidenten.html</a>
</div>
</div>

<div class = "source">
<div class = "quote">
Alpha-blockers used as antihypertensives<br>
Vasodilators used in cardiac diseases (Table 2: Fall-risk increasing drugs (FRIDs) according to the preliminary (September 2019) European consensus list.)
</div><div class = "quote">
Item 60: The patient is taking medication with a questionable efficacy and/or unfavourable safety profile e.g.: venotropic or vasodilatory drugs (e.g. cinnarizine, naftidrofuryl, pentoxifylline, piracetam). Questionable efficacy; Increased risk of adverse effects (e.g. orthostatic hypotension and falls) and interactions. 1st Re-evaluate whether indication is still present and prefer stopping therapy; 2nd Prefer non-pharmacological approach, a drug with a favourable risk/benefit ratio for a specified time, or refer to physician.
</div><div class="ref" name="7">
GheOP3S-tool draft 3 
</div>
</div>

<div class = "source">
<div class = "quote">
START/STOPP K3: vasodilatatoren (bijvoorbeeld a1-receptorblokkers, calciumantagonisten, langwerkende nitraten, ACE-remmers, angiotensine II-antagonisten) bij orthostatische hypotensie:
verhoogd risico op syncope, vallen
</div><div class="ref" name="9">
Wilma Knol, Monique M. Verduijn, A.C.A.M. (Rian) Lelie-van der Zande, Rob J. van Marum, J.R.B.J. (Koos) Brouwers, Tischa J.M. van der Cammen, Mirko Petrovic en Paul A.F. Jansen. Onjuist geneesmiddelgebruik bij ouderen opsporen: De herziene STOPP-en START-criteria. NED TIJDSCHR GENEESKD. 2015;159: A8904.
</div>
</div>

<div class = "source">
<div class = "quote">
<strong>Alpha-blockers (AB) used as antihypertensives</strong>
Fall-risk assessment: In which cases to consider withdrawal?
<ol>
<li>If hypotension, OH, or dizziness
</li>
</ol>
Is stepwise withdrawal needed? Consider monitoring after deprescribing.
<ol>

<ol>
<li>Monitor: hypertension
</li><li>Consider monitoring: palpitations, headache
</li>
</ol>
(If there is) No valid indication &rarr; Consider stopping the ABAHtapering the dose: can be tapered within 1-2 weeks. <br>
Safer alternatives available &rarr; Change to safer alternative<br>
Lower dose has not been tried &rarr; Try lower dose<br>
Otherwise &rarr; Perform a shared decision-making review with patient liaising with other relevant specialist as appropriate. Consider withdrawal if hypotension, orthostatic hypotension, or dizziness present. Take patient goals into account. <br>
Withdrawal &rarr; After withdrawal or dose reduction monitor for 1) changes in symptoms e.g., dizziness, orthostatic hypotension, 2) fall incidents and 3) blood pressure. Consider monitoring for: palpitations and headache.Organize follow-up on an individual basis taking into account patient factors including patient history, reason for stopping and possible occurrence of symptoms.
<strong>Vasodilators used in cardiac diseases</strong>
Fall-risk assessment: In which cases to consider withdrawal?
<ol>
<li>If hypotension, OH, or dizziness
</li>
</ol>
Is stepwise withdrawal needed?
<ol>
<li>Consider
</li></ol>
Monitoring after deprescribing
<ol>
<li>Monitor: symptoms of Angina Pectoris
</li>
</ol>
(If there is) No valid indication &rarr; Consider stopping the VD in stepwise manner: please see for possible strategies supplementary table 8.<br>
Safer alternatives available &rarr; Change to safer alternative.<br>
Lower dose has not been tried &rarr; Try lower dose.<br>
Otherwise &rarr; Consider changing dosing time. (If) No safer alternative is available: Perform a shared decision making with patient and possibly another specialist. Consider withdrawal if hypotension, OH, or dizziness present. Also, take patient goals into account.<br>
After withdrawal or dose reduction monitor for change in symptoms e.g., dizziness, and orthostatic hypotension, fall incidents and symptoms of angina pectoris. Organize follow-ups individual basis based e.g. on patient history, and possible occurrence of symptoms.
</div><div class="ref" name="10">
Lotta J Seppala, Mirko Petrovic, Jesper Ryg, Gulistan Bahat, Eva Topinkova, Katarzyna Szczerbinska, Tischa J M van der Cammen, Sirpa Hartikainen, Birkan Ilhan, Francesco Landi, Yvonne Morrissey, Alpana Mair, Marta Gutierrez-Valencia, Marielle H Emmelot-Vonk, Maria Angeles Caballero Mora, Michael Denkinger, Peter Crome, Stephen H D Jackson, Andrea Correa-Perez, Wilma Knol, George Soulis, Adalsteinn Gudmundsson, Gijsbertus Ziere, Martin Wehling, Denis O Mahony, Antonio Cherubini, Nathalie van der Velde, STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study by the EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs, Age and Ageing, 2020;, afaa249, https://doi.org/10.1093/ageing/afaa249
<br> Appendix IV: <a href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/ageing/PAP/10.1093_ageing_afaa249/3/appendixstoppfall2020-_clean_copy_afaa249.pdf?Expires=1623336792&Signature=sbJH-4l6FoenU~ziLjhjka3mrHDSm~6YkyRleMcUEraOPjUaJX~wQvDqWuxR8u-eJ01TXKS7CuR5jR1dykngxUpHrQRAJBITlFMktOAaus1TJTL67LYsNtCasMnmK~DMKRhDgegDvdCsyYNrU5heWIJWj~Wfl-IjBtZ0ow0qbwV~cF8VqArLMTRT-lWWuMKtlXkARQA9J~HVGsQevO30qQ7ZukSq1Im6auU5FqCsP5YPGFMzGhT3VbNDKq0jVkDHSkziUbReJZgoKh0uusPWZnp~~2q6yR~W~3MkDG~HARflmhHsXoCfBHoDYlbCfZooG-fIDqa4ir8LyXEbp50gxQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/ageing/PAP/10.1093_ageing_afaa249/3/appendixstoppfall2020-_clean_copy_afaa249.pdf?Expires=1623336792&Signature=sbJH-4l6FoenU~ziLjhjka3mrHDSm~6YkyRleMcUEraOPjUaJX~wQvDqWuxR8u-eJ01TXKS7CuR5jR1dykngxUpHrQRAJBITlFMktOAaus1TJTL67LYsNtCasMnmK~DMKRhDgegDvdCsyYNrU5heWIJWj~Wfl-IjBtZ0ow0qbwV~cF8VqArLMTRT-lWWuMKtlXkARQA9J~HVGsQevO30qQ7ZukSq1Im6auU5FqCsP5YPGFMzGhT3VbNDKq0jVkDHSkziUbReJZgoKh0uusPWZnp~~2q6yR~W~3MkDG~HARflmhHsXoCfBHoDYlbCfZooG-fIDqa4ir8LyXEbp50gxQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA</a>
</div>
</div>



</body>
